What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...

Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90 ...

Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and ...

Highlights:New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...

Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

LPOXY strengthens SIDIPREV™ pipeline to prevent the urgent threat of C. difficile. LPOXY will use these assets to advance SIDIPREV™, a novel therapy aimed at preventing Clostridioides ...